P621: Combination treatment of biologics with immunomodulator increases risk of infection after discharge in biologics naive steroid refractory acute severe ulcerative colitis patient: A KASID multicenter studyECCO’23 CopenhagenYear: 2023
Authors: Kim, S.J.(1)*;Lee, J.(1);Kim, D.H.(2);Park, S.H.(3);Kim, E.S.(4);Kim, K.O.(5);Lee, Y.J.(6);Song, E.M.(7);Kim, D.S.(8);
(1)College of Medicine- Chosun University, Internal Medicine, Gwangju, Korea- Republic Of;(2)Chonnam National University Hospital and Medical School, Internal Medicine, Gwangju, Korea- Republic Of;(3)Asan Medical Center, Internal Medicine, Seoul, Korea- Republic Of;(4)School of Medicine- Kyungpook National University, Internal Medicine, Daegu, Korea- Republic Of;(5)Yeungnam University hospital, Internal Medicine, Deagu, Korea- Republic Of;(6)Keimyung University Hospital, Internal Medicine, Daegu, Korea- Republic Of;(7)Ewha Womans University Seoul Hospital, Internal Medicine, Seoul, Korea- Republic Of;(8)Konyang University Hospital, Internal Medicine, Daejeon, Korea- Republic Of;IBD Research Group in Korean Association for the Study of the Intestinal Diseases (KASID)
P622: Change in Dietary Inflammatory Index Score in patients with Crohn's disease and healthy volunteers following the Groningen Anti Inflammatory Diet (GrAID)ECCO’23 CopenhagenYear: 2023
Authors: BarthDrs., I.(1)*;Stevens, C.L.(1);Campmans-Kuijpers, M.J.E.(1);Dijkstra, G.(1);
(1)University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, The Netherlands;
P623: Mucosal eosinophils as markers of post-induction vedolizumab response in paediatric Ulcerative ColitisECCO’23 CopenhagenYear: 2023
Authors: Musto, F.(1)*;Ranalli, M.(2);Giordano, C.(3);Bianchi, E.(2);Veraldi, S.(4);Oliva, S.(5);D'Arcangelo, G.(2);Aloi, M.(2);
(1)Sapienza University, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Roma, Italy;(2)Sapienza University, Paediatric Gastroenterology Unit- Department of Maternal and Child Health, Rome, Italy;(3)Sapienza University, Department of Radiology- Oncology and Pathology, Rome, Italy;(4)Sapienza University, Department of Anatomical- Histological- Forensic and Locomotor Apparatus Sciences, Rome, Italy;(5)Sapienza University, Paediatric Gastroenterology Unit-Department of Maternal and Child Health, Rome, Italy;
P624: Investigating the symptom burden among European patients with moderate-to-severe Crohn's disease using a real-world surveyECCO’23 CopenhagenYear: 2023
Authors: BurischPhD, J.(1)*;Hart, A.(2);Sturm, A.(3);Knight, H.(4);Rudolph, C.(5);Meadows, R.(4);Oortwijn, A.(5);Weatherby, S.(4);Rolph, R.(6);Dawod, F.(4);Armuzzi, A.(7);
(1)Hvidovre University Hospital, Department of Gastroenterology, Hvidovre, Denmark;(2)St Mark's Hospital, IBD Unit, Harrow, United Kingdom;(3)German Red Cross Hospital Berlin, Department of Internal Medicine - Gastroenterology, Berlin, Germany;(4)Adelphi Real World, Adelphi Real World, Bollington, United Kingdom;(5)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(6)Galapagos NV, Medical Affairs Department, Mechelen, Belgium;(7)IRCCS Humanitas Research Hospital, IBD Center, Milan, Italy;
P625: Randomized controlled trial on the effect of megaboluses of intravenous corticosteroids added to oral corticosteroids in the treatment of moderately active ulcerative colitisECCO’23 CopenhagenYear: 2023
Authors: Llaó, J.(1);Martín-Arranz, E.(2);Zabana, Y.(3);Navarro-Llavat, M.(4);Garcia-Planella, E.(5);Busquets, D.(6);Monfort, D.(7);Pineda, J.R.(8);Gutiérrez, A.(9);Villoria, A.(10);Menchén, L.(11);Bastida, G.(12);García-Alonso, F.J.(13);Rivero, M.(14);Chaparro, M.(15);Riestra, S.(16);Merino, O.(17);Rodríguez-Lago, I.(18);Barreiro-de-Acosta, M.(19);Domènech MoralPhD, E.(20)*;
(1)Xarxa Assistencial Althaia, Gastroenterology, Manresa, Spain;(2)H..U.La Paz, Gastroenterology, Madrid, Spain;(3)H.U.Mútua Terrassa & CIBEREHD, Gastroenterology, Terrassa, Spain;(4)H.Moisès Broggi, Gastroenterology, Sant Joan Despí, Spain;(5)H.. de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain;(6)H.U. Josep Trueta, Gastroenterology, Girona, Spain;(7)Consorci Sanitari de Terrassa, Gastroenterology, Terrassa, Spain;(8)H. Álvaro Cunqueiro, Gastroenterology, Vigo, Spain;(9)H. .G.U. Dr Balmis & ISABIAL, Gastroenterology, Alicante, Spain;(10)Consorci Sanitari Parc Taulí & CIBEREHD, Gastroenterology, Sabadell, Spain;(11)H.U. Gregorio Marañón & CIBEREHD, Gastroentrology, Madrid, Spain;(12).Universitari i Politècnic La Fe, Gastroenterology, Valencia, Spain;(13)H.U.Río Hortega, Gastroenterology, Valladolid, Spain;(14)H.U. Marqués de Valdecilla & IDIVAL, Gastroenterology, Santander, Spain;(15)H.U.La Princesa & CIBEREHD, Gastroenterology, Madrid, Spain;(16)H.U. Central Asturias, Gastroenterology, Oviedo, Spain;(17)H.Cruces, Gastroenteorology, Bilbao, Spain;(18)H. Galdakao, Gastroenterology, Galdakao, Spain;(19)Complejo hospitalario de Santiago, Gastroenterology, Santiago de Compostela, Spain;(20)Hospital Universitario Germans Trias i Pujol and CIBEREHD, Gastroenterology, Badalona, Spain;
P626: Safety of recombinant zoster vaccine in patients with Inflammatory Bowel Disease: a single centre experienceECCO’23 CopenhagenYear: 2023
Authors: Todeschini, A.(1)*;Geccherle, A.(1);Signoretto, P.(1);Variola, A.(1);
(1)IRCCS Sacro Cuore Don Calabria, IBD Unit, Negrar di Valpolicella, Italy;
P627: HLA DQA1*05 was not associated to primary non-response or loss of response to first anti-TNF in real world Inflammatory Bowel Disease patients.ECCO’23 CopenhagenYear: 2023
Authors: Pascual Oliver, A.(1)*;Cuarán, C.(1);Casas-Deza, D.(1,2);García-López, S.(1,2);Corsino-Roche, P.(1,2);Sierra Moros, E.(1);Julián-Gomara, A.B.(1);Vicente-Lidón, R.(1);
(1)Hospital Universitario Miguel Servet, Gastroenterology, Zaragoza, Spain;(2)Instituto de Investigación Sanitaria de Aragón, Gastroenterology, Zaragoza, Spain;
P628: Tofacitinib in pediatric ulcerative colitis: a retrospective multi-center experience from the Paediatric IBD Porto group of ESPGHANECCO’23 CopenhagenYear: 2023
Authors: Ledder, O.(1)*;Dubinsky, M.(2);Dolinger, M.(2);Fatima, A.(3);Suskind, D.(4);Scarlett, J.(4);Röeser, D.(5);Shouval, D.(6);Meyer, G.(7);Molle Rios, Z.(7);Pujol, G.(8);Lozano, A.(8);Kolho, K.L.(9);Rohani, P.(10);Hussey, S.(11);de Mejj, T.(12);Ayers, T.(13);Navas López, V.M.(14);Turner, D.(1);Tzivinikos, C.(15);
(1)Shaare Zedek Medical Center, Juliet Keidan Institute of Paediatric Gastroenterology, Jerusalem, Israel;(2)Icahn School of Medicine at Mount Sinai, Susan and Leonard Feinstein IBD Clinical Center, New York, United States;(3)Beaumont Children's Hospital, Pediatric Gastroenterology Department, Rochester, United States;(4)Seattle Children's Hospital Inflammatory Bowel Disease Center, Division of Gastroenterology, Seattle, United States;(5)Copenhagen University Hospital, Pediatric Department, Hvidovre, Denmark;(6)Schneider Children's Medical Center of Israel, Institute of Gastroenterology Nutrition and Liver Diseases, Petach Tikva, Israel;(7)Nemours Children's Hospital Wilmington, Division of Pediatric Gastroenterology, Wilmington, United States;(8)Hospital Sant Joan de Deu, Pediatric Gastroenterology- Hepatology and Nutrition Department, Barcelona, Spain;(9)Children's Hospital- Helsinki University, Pediatric Gastroenterology Department, Helsinki, Finland;(10)Children Medical Center- University of Medical Sciences, Pediatric Gastroenterology and Hepatology Research Center, Tehran, Iran- Islamic Republic Of;(11)Royal College of Surgeons of Ireland and University College Dublin, National Children's Research Centre, Dublin, Ireland;(12)Department of Pediatric Gastroenterology-, AG&M Research Institute- Amsterdam UMC, Amsterdam, The Netherlands;(13)Division of Pediatric Gastroenterology, Arkansas Children's Hospital- UAMS, Little Rock, United States;(14)IBIMA- Hospital Regional Universitario de Málaga, Pediatric Gastroenterology and Nutrition Unit, Málaga, Spain;(15)Paediatric Gastroenterology Department, Al Jalila Children's Specialty Hospital- Mohammed Bin Rashid University, Dubai, United Arab Emirates;
P629: Real-life treatment persistence and treatment outcomes of Finnish patients with Inflammatory Bowel Disease receiving vedolizumab as first-line biological treatmentECCO’23 CopenhagenYear: 2023
Authors: Ylisaukko-oja, T.(1);Af Björkesten, C.G.(2)*;Erbel, A.(2);Nuutinen, H.(3);Jussila, A.(4);Molander, P.(2);Koskela, R.(5);Blomster, T.(5);Pajala, M.(6);Ilus, T.(4);Haiko, P.(7);Kovac, B.(7);Silvola, S.(7);Smith, S.(1);Jokelainen, J.(1);Sipponen, T.(2);
(1)MedEngine Oy, Medical Data Science, Helsinki, Finland;(2)University of Helsinki and Helsinki University Hospital, Abdominal Center- Gastroenterology, Helsinki, Finland;(3)Turku University Hospital, Division of Gastroenterology- Department of Medicine, Turku, Finland;(4)Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland;(5)Oulu University Hospital, Department of Medicine- Division of Gastroenterology, Oulu, Finland;(6)Kuopio University Hospital, Department of Internal Medicine, Kuopio, Finland;(7)Takeda Oy, Takeda Oy, Helsinki, Finland;
P630: Upadacitinib Improves Clinical Outcomes in Patients with Moderate to Severely Active Crohn's Disease Irrespective of Previous Failure to Respond to Biologics or Conventional TherapiesECCO’23 CopenhagenYear: 2023
Authors: Schreiber, S.W.(1)*;Lim, A.(2);Lacerda, A.P.(3);Allegretti, J.R.(4);Watanabe, K.(5);Lukin, D.(6);Dubenco, E.(3);Ford, S.(3);Oomen, J.(3);Zhou, Q.(3);Liu, J.(3);Louis, E.(7);
(1)University Hospital Schleswig-Holstein- Christian Alrechts University, Department Internal Medicine, Kiel, Germany;(2)University of Alberta, Division of Gastroenterology- Department of Medicine, Edmonton, Canada;(3)AbbVie, none, North Chicago, United States;(4)Brigham and Women's Hospital, Division of Gastroenterology- Department of Internal Medicine, Boston, United States;(5)Hyogo Medical University, Division of Gastroenterology and Hepatology- Department of Internal Medicine-, Hyogo, Japan;(6)New York Presbyterian/Weill Cornell Medical Center, Department of Gastroenterology and Hepatology, New York, United States;(7)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology Department, Liège, Belgium;
P631: Long-term safety of vedolizumab versus other biologic agents in ulcerative colitis (UC) and Crohn's Disease (CD): Results from a large multinational prospective observational studyECCO’23 CopenhagenYear: 2023
Authors: Louis, E.(1)*;Sebastien, S.(2);Siegmund, B.(3);Bossuyt, P.(4);Danese, S.(5);de Boer, N.(6);Loftus, E.(7);Moum, B.(8);Peyrin-Biroulet, L.(9);Schreiber, S.(10);Zhou, J.(11);Wernicke, J.(11);Angellotti, E.(12);Siegel, C.(13);
(1)University of Liège, CHU Liège, Liège, Belgium;(2)Hull University Teaching Hospital, Gastroenterology, Hull, United Kingdom;(3)Charité–Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany;(4)Imelda GI Clinical Research Center, Imelda General Hospital, Bonheiden, Belgium;(5)University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(6)Amsterdam University Medical Center, Department of Gastroenterology and Hepatology- AGEM Research Institute, Amsterdam, The Netherlands;(7)Mayo Clinic College of Medicine and Science, Gastroenterology, Rochester- MN, United States;(8)Østfold Hospital Trust & University of Oslo, Gastroenterology, Oslo, Norway;(9)Nancy University Hospital, Gastroenterology, Nancy, France;(10)University Hospital Schleswig-Holstein, Gastroenterology, Kiel, Germany;(11)Takeda, Takeda, Cambridge- MA, United States;(12)Takeda, Takeda, Cambridge- MA, United Kingdom;(13)Dartmouth Hitchcock Medical Center-, Gastroenterology, Lebanon- NH, United States;
P632: Etrasimod induction therapy in moderately to severely active Crohn's disease: results from a phase 2, randomised, double-blind substudyECCO’23 CopenhagenYear: 2023
Authors: D'Haens, G.(1)*;Dubinsky, M.C.(2);Peyrin-Biroulet, L.(3,4);Danese, S.(5);Sands, B.E.(6);Wolf, D.C.(7);Yarur, A.(8);Chiorean, M.(9);Dray, D.(10);Modesto, I.(11);Tan, H.(12);Gu, G.(13);Lopez, C.(14);Su, C.(15);Zhang, J.(16);McDonnell, A.(17);Schreiber, S.(18);Feagan, B.G.(19);Vermeire, S.(20);
(1)University of Amsterdam, Gastroenterology, Amsterdam, The Netherlands;(2)Feinstein IBD Center- Mount Sinai, Gastroenterology, New York- New York, United States;(3)University of Lorraine- Inserm- NGERE, Gastroenterology, Nancy, France;(4)Groupe Hospitalier privé Ambroise Paré - Hartmann- Paris IBD center, Gastroenterology, Neuilly sur Seine, France;(5)IRCCS Ospedale San Raffaele and University Vita-Salute San Raffaele, Gastroenterology, Milan, Italy;(6)Dr. Henry D. Janowitz Division of Gastroenterology- Icahn School of Medicine at Mount Sinai, Gastroenterology, New York- New York, United States;(7)Atlanta Gastroenterology Associates, Gastroenterology, Atlanta- Georgia, United States;(8)Cedars-Sinai Medical Center, Gastroenterology, Los Angeles- California, United States;(9)IBD Center- Swedish Medical Center, Gastroenterology, Seattle- Washington, United States;(10)Pfizer Inc, Global Medical Affairs- Gastroenterology, New York- New York, United States;(11)Pfizer Inc, Global Medical Affairs- Gastroenterology, Madrid, Spain;(12)Pfizer Inc, Early Internal/External Development, New York- New York, United States;(13)Pfizer Inc, Clinical Development & Operations- Inflammation & Immunology, New York- New York, United States;(14)Arena Pharmaceuticals- which was acquired by Pfizer in March 2022, Clinical Development, San Diego- California, United States;(15)Pfizer Inc, Global Product Development, New York- New York, United States;(16)Pfizer Inc, Biostatistics, New York- New York, United States;(17)Pfizer Ltd., Safety Risk, Walton Oaks- Surrey, United Kingdom;(18)University Hospital Schleswig-Holstein- Department Internal Medicine I- Kiel University, Internal Medicine, Kiel, Germany;(19)University of Western Ontario/Alimentiv Inc, Gastroenterology, London- Ontario, Canada;(20)University Hospitals Leuven, Gastroenterology, Leuven, Belgium;
P633: Choice of first biologic in moderate to severe ulcerative colitis – a decision analysis using time-on-treatment and UK costsECCO’23 CopenhagenYear: 2023
Authors: Dhar, A.(1)*;Wilson, A.(2);Reid, V.(3);Clark, T.(4);Tibbatts, C.(5);Dallongeville, A.(6);Robertson, J.(7);Eaton, J.(8);Cranmer, H.(9);Owen, G.(8);
(1)County Durham and Darlington NHS Foundation Trust, Gastroenterology Department, Darlington, United Kingdom;(2)Belfast Health & Social Care Trust, Pharmacy Department, Belfast, United Kingdom;(3)Manchester University NHS Foundation Trust, Pharmacy Department, Manchester, United Kingdom;(4)Leeds Teaching Hospital NHS Trust, Gastroenterology Department, Leeds, United Kingdom;(5)Cardiff & Vale University Health Board, Gastroenterology Department, Cardiff, United Kingdom;(6)Takeda Pharmaceuticals International AG, Portfolio & Pipeline, Zurich, United Kingdom;(7)Takeda UK Ltd, Medical, London, United Kingdom;(8)Takeda UK Ltd, Market Access, London, United Kingdom;(9)Cranmer Consultancy, Health Economics, Sheffield, United Kingdom;
P634: Ustekinumab and vedolizumab as first-line biological therapy for inflammatory bowel disease. A multicenter study based on the ENEIDA registry.ECCO’23 CopenhagenYear: 2023
Authors: Calafat Sard, M.(1,2)*;Pascual, I.(3);Nos, P.(2,4); Barrio, J.(5); Gutiérrez, A.(2,6);Martín-Arranz, M.D.(7);Ricart, E.(2,8);Gomollón, F.(2,9);Sierra Ausín, M.(10); Huguet, J.M.(11);Guardiola, J.(12);Vera, I.(13);Varela, P.(14);Iglesias, E.(15);Garcia-Planella, E.(16);de Castro , L.(17);García Sepulcre , M.F.(18); Sicilia, B.(19);Fernández-Salazar, L.(20); Calvet, X.(2,21);Muñoz, F.(22); García-López, S.(23);Bermejo, F.(24);Ramos, L.(25);Martínez Montiel, P.(26);Lorente, R.(27);Cabriada, J.L.(28);Piqueras, M.(29);Marín-Jiménez, I.(30);Esteve, M.(2,31);Mesonero, F.(32); Sesé, E.(33);P. Gisbert, J.(2,34);Márquez, L.(35);Busquets, D.(36);Pajares, R.(37);Cañete, F.(2,38);Mañosa, M.(2,38);Domènech, E.(2,38);
(1)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department-IBD Unit, Badalona, Spain;(2)CIBERehd, Centro de Investigación Biomédica en Red Enfermedades Hepáticas y Digestivas, Madrid, Spain;(3)Hospital Clínic Universitari de València, Gastroenteroloy Department, Valencia, Spain;(4)Hospital Universitario y Politécnico la Fe, Gastroenterology Department, Valencia, Spain;(5)Hospital Universitario Río Hortega, Gastroenterology Department, Valladolid, Spain;(6)Hospital General Universitario Dr Balmis de Alicante- ISABIAL, Gastroenterology Department, Alicante, Spain;(7)Hospital Universitario La Paz, Gastroenterology Department, Madrid, Spain;(8)Hospital Clinic de Barcelona, Gastroenterology Department, Barcelona, Spain;(9)Hospital Clínico Universitario "Lozano Blesa"-Instituto de Investigación Sanitaria- IIS Aragón, Gastroenterology Department, Zaragoza, Spain;(10)Complejo Asistencial Universitario de León, Gastroenterology Department, León, Spain;(11)Consorcio Hospital General Universitario de Valencia, Gastroenterology Department, Valencia, Spain;(12)Hospital Universitari de Bellvitge, Gastroenterology Department, Hospitalet del Llobregat, Spain;(13)Hospital Universitario Puerta de Hierro Majadahonda, Gastroenterology Department, Majadahonda, Spain;(14)Hospital Universitario de Cabueñes, Gastroenterology Department, Gijón, Spain;(15)Hospital Universitario Reina Sofía de Córdoba, Gastroenterology Department, Córdoba, Spain;(16)Hospital de la Santa Creu i Sant Pau, Gastroenterology Department, Barcelona, Spain;(17)Hospital Alvaro Cunqueiro-Complexo Hospitalario Universitario de Vigo, Gastroenterology Department, Vigo, Spain;(18)Hospital General Universitario de Elche, Gastroenterology Department, Elche, Spain;(19)Hospital Universitario de Burgos, Gastroenterology Department, Burgos, Spain;(20)Hospital Clínico Universitario de Valladolid, Gastroenterology Department, Valladolid, Spain;(21)Corporació Sanitària Universitària Parc Taulí, Gastroenterology Department, Sabadell, Spain;(22)Hospital Universitario de Salamanca, Gastroenterology Department, Salamanca, Spain;(23)Hospital Universitario Miguel Servet, Gastroenterology Department, Zaragoza, Spain;(24)Hospital Universitario de Fuenlabrada- IdiPAZ, Gastroenterology Department, Fuenlabrada, Spain;(25)Hospital Universitario de Canarias, Gastroenterology Department, La Laguna, Spain;(26)Hospital Universitario Doce de Octubre, Gastroenterology Department, Madrid, Spain;(27)Hospital General Universitario de Ciudad Real, Gastroenterology Department, Ciudad Real, Spain;(28)Hospital Universitario de Galdakao, Gastroenterology Department, Galdakao, Spain;(29)Consorci Sanitari de Terrassa, Gastroenterology Department, Terrassa, Spain;(30)Hospital General Universitario Gregorio Marañón, Gastroenterology Department, Madrid, Spain;(31)Hospital Universitari Mutua Terrassa, Gastroenterology Department, Terrassa, Spain;(32)Hospital Universitario Ramón y Cajal, Gastroenterology Department, Madrid, Spain;(33)Hospital Universitario Arnau de Vilanova de Lleida, Gastroenterology Department, Lleida, Spain;(34)Hospital Universitario de la Princesa- IIS-Princesa- UAM- Madrid, Gastroenterology Department, Madrid, Spain;(35)Hospital del Mar de Barcelona, Gastroenterology Department, Barcelona, Spain;(36)Hospital Universitari de Girona Doctor Josep Trueta, Gastroenterology Department, Girona, Spain;(37)Hospital Universitario Infanta Sofía, Gastroenterology Department, Madrid, Spain;(38)Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain;on behalf of GETECCU.
P635: Risankizumab - real world Israeli data in severe refractory IBD patientsECCO’23 CopenhagenYear: 2023
Authors: Bar-Gil Shitrit, A.(1)*;Gil, Y.(2);Israeli, E.(3);Koslowsky, B.(2);Mazuz, B.(2);Israel, I.(2);Goldenberg, R.(2);Ben-Bassat, O.(4);Weisbrud, A.(5);Ledder, O.(6);Zinger, A.(7);Ben Horin, S.(8);Goldin, E.(2);Lahat, A.(8);
(1)Shaare Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel;(2)Share Zedek Medical Center, Department of Gastroenterology and Digestive Diseases, Jerusalem, Israel;(3)Wolfson Medical Center, Institute for Gastroenterology and Liver Diseases, Holon, Israel;(4)Barzilai Medical Center, Institute of Gastroenterology, Ashkelon, Israel;(5)Tel Aviv Sourasky Medical Center Ichilov, Institute of Gastrointestinal and Liver Diseases, Tel Aviv, Israel;(6)Share Zedek Medical Center, Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel;(7)Hadassah University Medical Center, Department of Gastroenterology and Liver Diseases, Jerusalem, Israel;(8)Sheba Medical Center Tel Hashomer, Institute of Gastrointestinal Diseases - Inflammatory Bowel Disease Clinic, Ramat Gan, Israel;
P636: Real-world clinical effectiveness and safety of vedolizumab and ustekinumab in biologic-naïve patients with Crohn's disease: Results from the EVOLVE Expansion studyECCO’23 CopenhagenYear: 2023
Authors: Ferrante, M.(1)*;Christensen, B.(2,3);Bressler, B.(4);Brett, N.(5);Bassel, M.(5);Kamble, P.(6);Adsul, S.(6);Gianchetti, L.(7);Scharl, M.(8);
(1)University Hospitals Leuven, Department of Gastroenterology and Hepatology, Leuven, Belgium;(2)The Royal Melbourne Hospital, Department of Gastroenterology, Melbourne, Australia;(3)The University of Melbourne, Department of Medicine, Melbourne, Australia;(4)St. Paul's Hospital, Division of Gastroenterology, Vancouver, Canada;(5)PPD- part of Thermo Fisher Scientific, Strategic and Scientific Affairs- PPAS and RWE, Montreal, Canada;(6)Takeda Pharmaceuticals, Gastroenterology, Cambridge, United States;(7)PPD- part of Thermo Fisher Scientific, Strategic and Scientific Affairs, Philadelphia, United States;(8)University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland;
P637: Targeting mucosal healing: dose optimization of Vedolizumab in IBD patients with inadequate endoscopic response to standard dosingECCO’23 CopenhagenYear: 2023
Authors: Dal Buono, A.(1)*;Gabbiadini, R.(1);Migliorisi, G.(1);Solitano, V.(1);Canziani, L.(2);Repici, A.(3,4);Armuzzi, A.(1,4);
(1)Humanitas Research Hospital - IRCCS, IBD Center, Rozzano- Milan, Italy;(2)University of Verona, Infectious Diseases Division- Department of Diagnostics and Public Health, Verona, Italy;(3)Humanitas Research Hospital - IRCCS, Department of Gastroenterology, Rozzano- Milan, Italy;(4)Humanitas University, Department of Biomedical Sciences, Pieve Emanuele- Milan, Italy;
P638: Effectiveness and safety of risankizumab induction therapy for 100 patients with Crohn's disease: a GETAID multicentre cohort studyECCO’23 CopenhagenYear: 2023
Authors: Fumery, M.(1)*;Defrance, A.(2);Roblin, X.(3);Altwegg, R.(4);Caron, B.(5);Hebuterne, X.(6);Carmen, S.(7);Meyer, A.(8);Nachury, M.(9);Laharie, D.(10);Nancey, S.(11);Le Berre, C.(12);Serrero, M.(13);Geyl, S.(14);Gilletta, C.(15);Ah Soune, P.(16);Duveau, N.(17);Uzza, M.(18);Abitbol, V.(19);Biron, A.(20);Tran Minh, M.L.(21);Paupard, T.(22);Vuitton, L.(23);Elgharabawy, Y.(2);Peyrin-biroulet, L.(5);
(1)Amiens University Hospital, Gastroenterology, Amiens Cedex 1, France;(2)GETAID, Getaid, Paris, France;(3)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(4)Montpellier University Hospital, Gastroenterology, Montpellier, France;(5)Nancy University Hospital, Gastroenterology, Nancy, France;(6)Nice University Hospital, Gastroenterology, Nice, France;(7)GH Ambroise Paré-Hartmann, Gastroenterology, Neuilly, France;(8)Kremlin-Bicetre, Gastroenterology, Paris, France;(9)Lille University Hospital, Gastroenterology, Lille, France;(10)Bordeaux University Hospital, Gastroenterology, Bordeaux, France;(11)Lyon University Hospital, Gastroenterology, Lyon, France;(12)Nantes University Hospital, Gastroenterology, Nantes, France;(13)Marseille University Hospital, Gastroenterology, Marseille, France;(14)Limoges University Hospital, Gastroenterology, Limoges, France;(15)Toulouse university Hospital, Gastroenterology, Toulouse, France;(16)Toulon Hospital, Gastroenterology, Toulon, France;(17)Roubaix Hospital, Gastroenterology, Roubaix, France;(18)Hopital Mondor, Gastroenterology, Creteil, France;(19)Hopital Cochin, Gastroenterology, Paris, France;(20)Reims University Hospital, Gastroenterology, Reims, France;(21)Saint Louis Hospital, Gastroenterology, Paris, France;(22)Dunkerque Hospital, Gastroenterology, Dunkerque, France;(23)Besançon University Hospital, Gastroenterology, Besançon, France;GETAID
P639: Percutaneous drainage vs surgery as definitive treatment for anastomotic leak after intestinal resection in patients with Crohn's disease.ECCO’23 CopenhagenYear: 2023
Authors: Belvedere, A.(1)*;Dajti, G.(1);Larotonda, C.(1);Angelicchio, L.(1);Rizzello, F.(2);Gionchetti, P.(2);Poggioli, G.(1);Rottoli, M.(1);
(1)IRCCS Azienda Ospedaliero Universitaria di Bologna- Alma Mater Studiorum University of Bologna, Surgery of the Alimentary Tract, Bologna, Italy;(2)IRCCS Azienda Ospedaliero Universitaria di Bologna- Alma Mater Studiorum University of Bologna, IBD unit, Bologna, Italy;
P640: Serologic response and safety after third dose of the COVID-19 BNT162b2 vaccine in patients with Inflammatory Bowel DiseasesECCO’23 CopenhagenYear: 2023
Authors: Edelman-Klapper, H.(1,2)*;Rabinowitz, K.M.(1,3); Zittan, E.(4,5);Bar-Gil Shitrit, A.(6,7);Goren, I.(1,2);Avni-Biron, I.(1,2);Ollech, J.E.(1,2);Lichtenstein, L.(8);Banai-Eran, H.(1,2);Yanai, H.(1,2);Snir, Y.(1,2);Pauker, M.H.(1,2);Friedenberg, A.(1);Levy-Barda, A.(9);Segal, A.(10);Broitman, Y.(1,2);Maoz, E.(11);Ovadia, B.(12);Aharoni Golan, M.(1,2);Shachar, E.(2,13);Ben-Horin, S.(2,13);Mor, M.(11);Ben Zvi, H.(2,14);Perets, T.T.(15,16);Eliakim, R.(2,13);Barkan, R.(1);Navon, M.(17);Gal-Tanamy, M.(18);Freund, N.T.(17);Goren, S.(19);Cohen, D.(19);Dotan, I.(1,2);
(1)Rabin Medical Center, Division of Gastroenterology, Petah Tikva, Israel;(2)Tel Aviv University, Sackler Faculty of Medicine, Tel Aviv, Israel;(3)Tel Aviv University, Felsenstein Medical Research Center- Sackler School of Medicine, Tel Aviv, Israel;(4)Emek Medical Center, The Abraham and Sonia Rochlin IBD Unit- Department of Gastroenterology, Afula, Israel;(5)Technion-Israel Institute of Technology, Rappaport Faculty of Medicine, Haifa, Israel;(6)Shaare Zedek Medical Center, Digestive diseases institute, Jerusalem, Israel;(7)Hebrew University of Jerusalem, Faculty of Medicine, Jerusalem, Israel;(8)Clalit Health Services, Gastroenterology, Petah Tikva, Israel;(9)Rabin Medical Center, Biobank- Department of Pathology, Petah Tikva, Israel;(10)Soroka University Medical Center, The Institute of Gastroenterology and Hepatology, Beer-Sheva, Israel;(11)Clalit Health Services, Gastroenterology, Tel Aviv, Israel;(12)Hillel Yaffe Medical Center, Department of Gastroenterology and Hepatology, Hadera, Israel;(13)Sheba Medical Center, Department of Gastroenterology, Ramat Gan, Israel;(14)Rabin Medical Center, Microbiology lab, Petah Tikva, Israel;(15)Rabin Medical Center, Division of Gastroenterology- Gastroenterology Laboratory, Petah Tikva, Israel;(16)Ariel University, Adelson School of Medicine, Ariel, Israel;(17)Tel Aviv University, Department of Clinical Microbiology and immunology- Sackler Faculty of Medicine, Tel Aviv, Israel;(18)Bar-Ilan University, Molecular Virology Lab- The Azrieli Faculty of Medicine, Safed, Israel;(19)Tel Aviv University, School of Public Health- Sackler Faculty of Medicine, Tel Aviv, Israel;the REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]